Other
Anticoagulation
1
Pipeline Programs↗
11
Active Trials↗
8
Companies Involved↗
Anticoagulation is an early-stage landscape with 1 program across 8 companies. The most active players are ARCA Biopharma, Inc., AMAG Pharmaceuticals, Inc., Portola Pharmaceuticals. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Approved
No programs
Analysis
Trial Status
82
clinical trials
Completed37 · 45%
Unknown status23 · 28%
Recruiting9 · 11%
Terminated6 · 7%
Withdrawn4 · 5%
Active, not recruiting2 · 2%
Other1 · 1%
Clinical Trials
Trial Activity
82 trials
A Novel Strategy of ECMO Management Using Nafamostat for Regional Combined With Low Intensity Systematic Anticoagulation
Recruiting·—·N/A·NCT06676085·60 enrolled
Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation
Recruiting·—·N/A·NCT03532399·30 enrolled
Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT04066764·200 enrolled
Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
Active, not recruiting·—·Phase 3·NCT05825573·340 enrolled
Combined Anti-IL6R and Anticoagulation Therapy in Advanced NPC Patients
Active, not recruiting·—·N/A·NCT06442709·100 enrolled
Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)
Completed·—·Phase 4·NCT02735902·170 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)